A new multicenter randomized trial published in the New England Journal of Medicine demonstrated yet again that high flow nasal cannula (HFNC) is not a viable alternative to CPAP for primary respiratory support in neonates.
Study Shows Clinicians Using Vapotherm® Oxygen Assist Module Prototype Significantly Better at Achieving Target SpO2 in NICU than Manual Titration
In November 2018, the Archives of Disease in Childhood: Fetal & Neonatal edition published the results of a prospective, two-center, order-randomized cross-over study performed at two NICUs in the UK, designed to evaluate the performance of Vapotherm’s® forthcoming Oxygen Assist Module (OAM) technology.
Dexmedetomidine During Noninvasive Ventilation: Dr. Shein from Rainbow Babies and Children’s Hospital Cleveland, OH Comments
In April 2018, Steven Shein, MD from Rainbow Babies and Children’s Hospital Cleveland, OH’s Division of Pediatric Critical Care Medicine, Department of Pediatrics, published an editorial in in Pediatric Critical Care Medicine titled “Dexmedetomidine During Noninvasive Ventilation: Different Acuity, Different Risks?.”
In July 2016, Reynolds and colleagues published a single-center, observational pilot study in Archives of Disease in Childhood — Fetal and Neonatal Edition, titled “Stabilization of Premature Infants in the Delivery Room with Nasal High Flow.” The study included 28 premature (<30 weeks of gestation) infants with primary outcomes…
Cannulaide® is a transparent adhesive designed to relieve irritation of the nares in neonates who are placed on nasal CPAP. The product creates an air seal to support the pressure mechanism of CPAP while ensuring that the cannula prongs do not fully occlude the neonate’s nares and thereby don’t lead to a potential Hospital Acquired Pressure Injury (HAPI).
What’s the Difference Between Vapotherm® High Velocity Therapy vs High Flow Nasal Cannula? The Ten Clinical Studies to Read
Vapotherm high velocity therapy often gets conflated with commodity high flow oxygen products, also commonly known as High Flow Nasal Cannula (HFNC). Many studies don’t differentiate between the two, though this is slowly changing in the medical field as randomized controlled trial evidence showed high velocity therapy to have outcomes.
The results of the prospective, randomized controlled trial were published by Collins and colleagues in May 2013 in The Journal of Pediatrics titled “A Randomized Controlled Trial to Compare Heated Humidified High-Flow Nasal Cannulae with Nasal Continuous Positive Airway Pressure Postextubation in Premature Infants”.
While the association between HFNC and BPD/mortality should raise concern, there are major limitations of this analysis. Please consider the following points when interpreting this study.
In September of 2016, the report of the HIPSTER trial came to press in the New England Journal of Medicine. The HIPSTER trial was a prospective, multicenter randomized controlled trial evaluating the outcomes for High Flow Nasal Cannula (HFNC) compared to nasal continuous positive airway pressure (nCPAP) when used as a primary means of respiratory support in neonates.
According to the Centers for Disease Control, the total national healthcare expenditure in 2015 was $3.2 trillion, and 32.3% of that is for hospital care. The cost of healthcare has been steadily increasing and is projected to continue to rise. In 2014 there were 137.8 million emergency department visits, a 14.8% increase since 2006.
With the patient in supine position, make sure his/her face is clean.
Use DuoDERM CGF Extra Thin Dressings (1-3/4″ x 1-1/2″).
Peel off the backing of each duoDERM Spot and place them halfway between the patient’s ear and corner of their lip.
Clinicians have historically utilized nCPAP/NIPPV as primary non-invasive therapy. Several randomized controlled trials have…
High flow nasal cannula (HFNC) is commonly used to support neonates with respiratory distress syndrome (RDS), but reports suggest…